Trial Profile
Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms TROJAN-C
- 25 Jan 2023 Planned End Date changed from 30 Dec 2022 to 30 Dec 2023.
- 25 Jan 2023 Planned primary completion date changed from 30 Dec 2022 to 30 Dec 2023.
- 25 Jan 2023 Status changed from recruiting to active, no longer recruiting.